Search

Your search keyword '"Zhou Yingfeng"' showing total 3 results
Start Over Author "Zhou Yingfeng" Topic carcinoma, non-small-cell lung
3 results on '"Zhou Yingfeng"'

1. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.

Author

Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, and Zhou Y

Subjects
Adult, Carboplatin administration & dosage, Carboplatin pharmacology, Cisplatin administration & dosage, Cisplatin pharmacology, Female, Humans, Male, Middle Aged, Multivariate Analysis, Oligonucleotide Array Sequence Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols pharmacology, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, DNA-Binding Proteins genetics, Drug Resistance, Neoplasm genetics, Endonucleases genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Polymorphism, Single Nucleotide, Xeroderma Pigmentosum Group D Protein genetics
Abstract

Background and Objective: DNA repair capacity is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in polymorphisms of DNA repair gene ERCC1 (excision repair cross-complementation group 1) and XPD (ERCC2, excision repair cross-complementation group 2) were associated with the tumor response in advanced non-small-cell lung cancer (NSCLC) patients received platinum-based chemotherapy in Chinese population., Methods: Totally 115 patients with advanced NSCLC were routinely treated with cisplatin- or carboplatin-based chemotherapy, and clinical response was evaluated after 2 cycles. Three dimensions (3-D) polyacrylamide gel-based DNA microarray method was used to evaluate the genotypes of ERCC1 Asn118Asn (354 CT), Gln504Lys (8092 CA) and XPD Lys751Gln (35931 AC)., Results: The C→T change of ERCC1 Asn118Asn polymorphism and the C→A change of ERCC1 Gln504Lys polymorphism have statistically significant association with elevated or descendent platinum-based chemotherapy response respectively., Conclusion: The polymorphic status of ERCC1 might be the promising ancillary marker for predicting treatment response of advanced stage NSCLC patients. The DNA microarray-based method is accurate, high-throughput and inexpensive, suitable for SNP genotyping in a large number of individuals.

Published
2010
Full Text
View/download PDF

2. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.

Author

Feng J, Sun X, Sun N, Qin S, Li F, Cheng H, Chen B, Cao Y, Ma J, Cheng L, Lu Z, Ji J, and Zhou Y

Subjects
Adult, Aged, Aged, 80 and over, Carboplatin administration & dosage, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Cisplatin administration & dosage, DNA-Binding Proteins genetics, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Docetaxel, Endonucleases genetics, Female, Gene Frequency, Genotype, Humans, Logistic Models, Lung Neoplasms genetics, Lung Neoplasms pathology, Male, Middle Aged, Nuclear Proteins genetics, Paclitaxel administration & dosage, Taxoids administration & dosage, Transcription Factors genetics, Treatment Outcome, Vinblastine administration & dosage, Vinblastine analogs & derivatives, Vinorelbine, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Polymorphism, Single Nucleotide, Xeroderma Pigmentosum Group A Protein genetics
Abstract

DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the Aright curved arrow G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.

Published
2009
Full Text
View/download PDF

3. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients

Author

Cheng Lu, Xinchen Sun, Cao Yuandong, Chen Bao-an, Zhou Yingfeng, Lu Zuhong, Cheng Hongyan, Ning Sun, Ji Jiazhong, Fan Li, Qin Shukui, and Feng Ji-Feng

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Pathology, Lung Neoplasms, Genotype, Population, non-small cell lung cancer (NSCLC), Antineoplastic Agents, Polymerase Chain Reaction, Polymorphism, Single Nucleotide, Carboplatin, chemistry.chemical_compound, XRCC1, Carcinoma, Non-Small-Cell Lung, Internal medicine, Humans, Medicine, Lung cancer, education, Aged, Oligonucleotide Array Sequence Analysis, Cisplatin, education.field_of_study, Predictive marker, business.industry, Gene Expression Profiling, Nuclear Proteins, Cancer, Middle Aged, Endonucleases, Prognosis, medicine.disease, DNA-Binding Proteins, X-ray Repair Cross Complementing Protein 1, chemistry, Drug Resistance, Neoplasm, Female, business, Transcription Factors, medicine.drug
Abstract

Platinum-based chemotherapeutics is the most common regimens for advanced NSCLC patients. However, it is difficult to identify platinum resistance in clinical treatment. Genetic factors are thought to represent important determinants of drug efficacy. In this study, we investigated whether single nucleotide polymorphisms (SNPs) in Xeroderma pigmentosum group G (XPG) and X-ray repair cross complementing group 1 (XRCC1) were associated with the tumor response in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy in Chinese population. Totally 82 patients with advanced NSCLC were routinely treated with cisplatin or carboplatin-based chemotherapy, and clinical response was evaluated after 2–3 cycles. And 3D (three dimensions) polyacrylamide gel-based DNA microarray method was used to evaluate the genotypes of XRCC1 194 Arg/Trp, XRCC1 399Arg/Gln, XPG 46His/His and XPG 1104His/Asp in DNA from peripheral lymphocytes. We found that there was a significantly increased chance of treatment response to platinum-based chemotherapy with the XRCC1 194Arg/Trp genotype (odds ratio 0.429; 95% CI 0.137–1.671; P = 0.035). The polymorphism of XPG 46His/His was found to be associated with clinical response in NSCLC patients P = 0.047, not detected between chemotherapy response and SNPs of XRCC1 399Arg/Gln or XPG 1104His/Asp (P = 0.997 0.561, respectively). Our study showed that the polymorphic status of XRCC1 194Arg/Trp might be a predictive marker of treatment response for advanced NSCLC patients and those of XPG His46His was associated with susceptibility of chemotherapy. The 3D polyacrylamide gel-based DNA microarray method was accurate, high-throughput and inexpensive, especially suitable for a large scale of SNP genotyping in population.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results